Key Takeaways
- Central serous chorioretinopathy can recur after the initial episode has resolved, even following successful treatment.
- Recurrence does not necessarily mean that previous treatment failed; the condition can have a fluctuating or recurrent course.
- Follow-up eye examinations and imaging can help detect returning subretinal fluid before it causes significant visual changes.
- Treatment for recurrent disease depends on factors such as persistence of fluid, previous treatment, symptoms, and whether the condition has become chronic.
Central serous chorioretinopathy (CSCR) is an eye condition in which fluid collects beneath the retina, particularly around the macula, the area responsible for detailed central vision. This can cause blurred or distorted vision, dark or dim areas in the visual field, and changes in how straight lines appear.
Many acute cases improve without treatment, while persistent or recurrent cases may require intervention. Because CSCR can return after an episode has resolved, understanding recurrence is an important part of long-term eye care.
Can Central Serous Chorioretinopathy Return?
Central serous chorioretinopathy can recur after the initial episode has resolved, including after successful central serous chorioretinopathy treatment. Recurrence is recognized as part of the condition’s clinical course, and some individuals may experience more than one episode over time [1].
A recurrence may involve a new accumulation of subretinal fluid or renewed leakage beneath the retina. The timing can vary considerably between individuals, which is why continued monitoring may be recommended even after vision has improved.
Importantly, recurrence should not automatically be interpreted as central serous chorioretinopathy treatment failure. Different treatments aim to reduce active leakage and resolve fluid, but they may not eliminate every factor associated with CSCR.
Why Can CSCR Recur?
The exact mechanisms behind CSCR are not completely understood. Research suggests that changes involving the choroid, the vascular layer beneath the retina, and retinal pigment epithelium may contribute to the development of the condition [2].
Certain factors have also been associated with CSCR. Corticosteroid exposure, for example, is an important factor that ophthalmologists may consider when assessing a patient. Steroids can be taken in several forms, including tablets, injections, inhaled medications, nasal sprays, or skin preparations [3].
This does not mean that every person using steroids will develop CSCR or that someone should stop a prescribed medication without medical advice. Instead, patients should inform their healthcare professional about all medications they use.
How Treatment Affects Recurrence
The appropriate central serous chorioretinopathy treatment depends on whether the condition is acute, persistent, or chronic. Some acute cases can be monitored because the fluid may resolve spontaneously within several months. Persistent or chronic disease may require treatment to reduce the risk of ongoing retinal damage.
Photodynamic therapy (PDT) is an established treatment option, particularly for chronic CSCR. Research has found that reduced-dose or reduced-fluence PDT can help resolve subretinal fluid in appropriate patients [4].
Long-term follow-up research has also suggested that recurrence patterns can differ according to treatment method. In one study of chronic CSCR, patients who received half-dose PDT had fewer recurrences of subretinal fluid during follow-up than those treated with high-density subthreshold micropulse laser [5].
However, individual outcomes can differ, and central serous chorioretinopathy treatment decisions should be made by a retinal specialist based on the patient’s clinical findings.
Treatment and Recurrence at a Glance
| Situation | Possible approach | Why follow-up matters |
| Acute CSCR | Observation may be appropriate in many cases | Confirms whether fluid resolves |
| Persistent CSCR | CSCR treatment may be considered | Ongoing fluid can affect retinal structures |
| Chronic CSCR | PDT or another specialist-directed treatment may be considered | Monitoring helps assess treatment response |
| Recurrent CSCR | Previous treatment and current findings guide management | Detects returning fluid and changes in vision |
The central serous chorioretinopathy treatment plan may therefore change if the disease returns. A person who previously required treatment may not necessarily need exactly the same approach during a later episode.
What Does Recurrence Feel Like?
Some people notice visual changes when CSCR returns, while others may have relatively subtle symptoms. Possible symptoms include blurred central vision, distorted straight lines, reduced contrast, a dim or dark area in central vision, or objects appearing different in size or shape.
Because symptoms can sometimes be mild, relying only on vision changes may not be sufficient for monitoring recurrent disease. Optical coherence tomography (OCT) is commonly used by eye specialists to examine the retina and identify subretinal fluid [6].
A new change in central vision should therefore be assessed rather than assumed to be temporary. Prompt evaluation can help determine whether the symptoms are related to recurrent CSCR or another eye condition.
Can Recurrence Cause Permanent Vision Problems?
A single episode does not necessarily lead to permanent vision loss. However, persistent or repeated episodes may increase the risk of damage to retinal pigment epithelial cells and photoreceptors. Chronic CSCR has therefore received particular attention because prolonged subretinal fluid can affect retinal structure and visual function.
This is one reason monitoring remains important after the initial episode appears to have resolved. The goal is not simply to improve vision temporarily but also to identify persistent or returning fluid that could affect the retina over time.
The CSCR treatment approach may be adjusted when recurrent or chronic disease is identified.
What Should You Do If Symptoms Return?
If visual distortion, blurring, or another unusual change occurs after previous CSCR, arrange an eye examination rather than assuming that the symptoms will resolve on their own.
An ophthalmologist may perform a dilated retinal examination and OCT imaging. Additional imaging, such as fluorescein angiography or indocyanine green angiography, may be used when more detailed information about leakage or the choroid is needed.
The results can help determine whether active CSCR has returned and whether observation or treatment of CSCR is appropriate.
Patients should also tell their eye specialist about previous CSCR episodes, treatments received, medications, and any corticosteroid exposure. This information can help guide the next step.
Can Recurrence Be Prevented?
There is no guaranteed way to prevent CSCR from returning. However, identifying and addressing relevant risk factors may form part of long-term management.
Corticosteroid exposure is one factor that deserves discussion with a healthcare professional. Stress has also been associated with CSCR, although the relationship is complex and cannot be considered a simple cause-and-effect relationship.
Rather than attempting to manage potential triggers independently, patients should discuss their individual circumstances with their ophthalmologist. The central serous chorioretinopathy treatment strategy should always reflect the person’s eye findings, medical history, and risk factors.
Long-Term Monitoring Matters
Successful resolution of CSCR is encouraging, but it does not necessarily mean that the condition can never return. Recurrence is possible, and the risk varies among individuals and clinical circumstances.
Regular follow-up can help identify recurrent or persistent subretinal fluid and assess whether retinal changes are affecting vision. This is particularly relevant for people who have experienced chronic or repeated episodes.
For recurrent disease, the central serous chorioretinopathy treatment may involve reassessing the original diagnosis, reviewing previous therapy, evaluating current retinal findings, and considering whether another intervention is appropriate.
Conclusion
Central serous chorioretinopathy can recur after treatment, but recurrence does not mean that a previous treatment was unsuccessful. CSCR can follow different patterns, ranging from a single episode that resolves spontaneously to persistent or recurrent disease requiring ongoing management.
The central serous chorioretinopathy treatment used for one episode may not necessarily be the same approach recommended for a recurrence. Decisions depend on factors such as the duration of subretinal fluid, visual symptoms, retinal changes, previous treatment, and the overall clinical picture.
For anyone with a history of CSCR, ongoing ophthalmic follow-up and prompt assessment of new visual symptoms can help support timely management. The central serous chorioretinopathy treatment plan should ultimately be individualized by an eye-care professional, particularly when the condition becomes recurrent or chronic.
References
- Zhang, X., Zhuang, X., Dong, J., Fu, B., & Xu, L. (2022). Factors for recurrence in acute central serous chorioretinopathy patients underwent one-third dose verteporfin photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 39, 102984. https://doi.org/10.1016/j.pdpdt.2022.102984
- Zhang, X., Lim, C. Z. F., Chhablani, J., & Wong, Y. M. (2023). Central serous chorioretinopathy: Updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, 10, 33. https://doi.org/10.1186/s40662-023-00349-y
- Ge, G., Zhang, Y., Zhang, Y., Xu, Z., & Zhang, M. (2020). Corticosteroids usage and central serous chorioretinopathy: A meta-analysis. Graefe’s Archive for Clinical and Experimental Ophthalmology, 258(1), 71–77. https://doi.org/10.1007/s00417-019-04486-w
- van Dijk, E. H. C., Fauser, S., Breukink, M. B., Blanco-Garavito, R., Groenewoud, J. M. M., Keunen, J. E. E., Peters, P. J. H., Dijkman, G., Souied, E. H., MacLaren, R. E., Querques, G., Downes, S. M., Hoyng, C. B., & Boon, C. J. F. (2018). Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE trial. Ophthalmology, 125(10), 1547–1555. https://doi.org/10.1016/j.ophtha.2018.04.021
- van Rijssen, T. J., van Dijk, E. H. C., Scholz, P., Breukink, M. B., Dijkman, G., Peters, P. J. H., Tsonaka, R., Keunen, J. E. E., MacLaren, R. E., Hoyng, C. B., Downes, S. M., Fauser, S., & Boon, C. J. F. (2021). Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. Acta Ophthalmologica, 99(7), 805–811. https://doi.org/10.1111/aos.14775
- Fung, A. T., Yang, Y., & Kam, A. W. (2023). Central serous chorioretinopathy: A review. Clinical & Experimental Ophthalmology, 51(3), 243–270. https://doi.org/10.1111/ceo.14201
